Cancer Research and Treatment

Original Articles

Gastrointestinal Cancer

Development and Validation of a Symptom-Focused Quality of Life Questionnaire (KOQUSS-40) for Gastric Cancer Patients after Gastrectomy: Bang Wool Eom, Joongyub Lee, In Seob Lee, Young-Gil Son, Keun Won Ryu, Sung Geun Kim, Hyoung-Il Kim, Young-Woo Kim, Seong-Ho Kong, Oh Kyoung Kwon, Ji-Ho Park, Ji Yeong An, Chang Hyun Kim, Byoung-Jo Suh, Hong Man Yoon, Myoung Won Son, Ji Yeon Park, Jong-Min Park, Sang-Ho Jeong, Moon-Won Yoo, Geum Jong Song, Han-Kwang Yang, Yun-Suhk Suh, Ki Bum Park, Sang-Hoon Ahn, Dong Woo Shin, Ye Seob Jee, Hye-Seong Ahn, Sol Lee, Jae Seok Min, Haejin In, Ahyoung Kim, Hoon Hur, Hyuk-Joon Lee, on behalf of KOrean QUality of life in Stomach cancer patients Study group (KOQUSS); Cancer Res Treat. 2021;53(3):763-772. Published online December 29, 2020; DOI: https://doi.org/10.4143/crt.2020.1270

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patients who have undergone gastrectomy have unique symptoms that are not appropriately assessed using currently available tools. This study developed and validated a symptom-focused quality of life (QoL) questionnaire for patients who have received gastrectomy for gastric cancer. Materials and Methods Based on a literature review, patient interviews, and expert consultation by the KOrean QUality of life in Stomach cancer patients Study group (KOQUSS), the initial item pool was developed. Two large-scale developmental studies were then sequentially conducted for exploratory factor analyses for content validity and item reduction. The final item pool was validated in a separate cohort of patients and assessed for internal consistency, test-retest reliability, construct validity, and clinical validity.
Results
The initial questionnaire consisted of 46-items in 12 domains. Data from 465 patients at 11 institutions, followed by 499 patients at 13 institutions, were used to conduct item reduction and exploratory factor analyses. The final questionnaire (KOQUSS-40) comprised 40 items within 11 domains. Validation of KOQUSS-40 was conducted on 413 patients from 12 hospitals. KOQUSS-40 was found to have good model fit. The mean summary score of the KOQUSS-40 was correlated with the EORTC QLQ-C30 and STO22 (correlation coefficients, 0.821 and 0.778, respectively). The KOQUSS-40 score was also correlated with clinical factors, and had acceptable internal consistency (> 0.7). Test-retest reliability was greater than 0.8. Conclusion The KOQUSS-40 can be used to assess QoL of gastric cancer patients after gastrectomy and allows for a robust comparison of surgical techniques in clinical trials.

Citations

Citations to this article as recorded by

Global status of research on gastrointestinal cancer patients’ quality of life: A bibliometric and visual analysis from 2003 to 2023
Xiaoqin Wang, Caihua Wang, Wenjin Han, Jiaru Sun, Zhaozhao Hui, Shuangyan Lei, Huili Wu, Xiaohong Liu
Heliyon.2024; 10(1): e23377. CrossRef
Development and Feasibility Assessment of Mobile Application-Based Digital Therapeutics for Postoperative Supportive Care in Gastric Cancer Patients Following Gastrectomy
Ji-Hyeon Park, Hyuk-Joon Lee, JeeSun Kim, Yo-Seok Cho, Sunjoo Lee, Seongmin Park, Hwinyeong Choe, Eunhwa Song, Youngran Kim, Seong-Ho Kong, Do Joong Park, Byung-Ho Nam, Han-Kwang Yang
Journal of Gastric Cancer.2024; 24(4): 420. CrossRef
Effect of Four Main Gastrectomy Procedures for Proximal Gastric Cancer on Patient Quality of Life: A Nationwide Multi-Institutional Study
Koji Nakada, Akitoshi Kimura, Kazuhiro Yoshida, Nobue Futawatari, Kazunari Misawa, Kuniaki Aridome, Yoshiyuki Fujiwara, Kazuaki Tanabe, Hirofumi Kawakubo, Atsushi Oshio, Yasuhiro Kodera
Journal of Gastric Cancer.2023; 23(2): 275. CrossRef
Quality of life after gastric cancer surgery
Jae Kyun Park, Hyuk-Joon Lee
Foregut Surgery.2023; 3(2): 27. CrossRef
Long-term Functional and Patient-reported Outcomes Between Intra-corporeal Delta-shaped Gastroduodenostomy and Gastrojejunostomy After Laparoscopic Distal Gastrectomy
Sin Hye Park, Hong Man Yoon, Keun Won Ryu, Young-Woo Kim, Mira Han, Bang Wool Eom
Journal of Gastric Cancer.2023; 23(4): 561. CrossRef
Potential Applicability of Local Resection With Prophylactic Left Gastric Artery Basin Dissection for Early-Stage Gastric Cancer in the Upper Third of the Stomach
Yoshimasa Akashi, Koichi Ogawa, Katsuji Hisakura, Tsuyoshi Enomoto, Yusuke Ohara, Yohei Owada, Shinji Hashimoto, Kazuhiro Takahashi, Osamu Shimomura, Manami Doi, Yoshihiro Miyazaki, Kinji Furuya, Shoko Moue, Tatsuya Oda
Journal of Gastric Cancer.2022; 22(3): 184. CrossRef
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Alison Rowsell, Samantha C. Sodergren, Vassilios Vassiliou, Anne-Sophie Darlington, Marianne G. Guren, Bilal Alkhaffaf, Chantelle Moorbey, Kristopher Dennis, Mitsumi Terada
Gastric Cancer.2022; 25(4): 665. CrossRef
Patient-reported gastrointestinal symptoms following surgery for gastric cancer and the relative risk factors
Rui Xu, Qiong Gu, Shuomeng Xiao, Ping Zhao, Zhi Ding
Frontiers in Oncology.2022;[Epub] CrossRef
Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial
Bang Wool Eom, Dong-Hoe Koo, Ji Yeong An, Han Hong Lee, Hyoung-Il Kim, Hoon Hur, Moon-Won Yoo, Min-Hee Ryu, Hyuk-Joon Lee, Su Mi Kim, Ji-Ho Park, Jae Seok Min, Kyung Won Seo, Sang-Ho Jeong, Oh Jeong, Oh Kyoung Kwon, Seung Wan Ryu, Chang Hak Yoo, Jae Moon
BMJ Open.2021; 11(12): e056187. CrossRef

8,975 View
335 Download
8 Web of Science
9 Crossref

The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer: Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha; Cancer Res Treat. 2019;51(4):1411-1419. Published online February 25, 2019; DOI: https://doi.org/10.4143/crt.2018.663

Abstract PDF Supplementary Material PubReader ePub

Purpose
We previously demonstrated that CD44v9 and Ki-67 played an important role in predicting poor prognosis of early gastric cancer (EGC). However, little is known about combined use of both biomarkers as prognostic biomarker. The present study was performed to investigate the significance of CD44v9 and Ki-67 expression as a combination biomarker for EGC.
Materials and Methods
With tissue microarray for 158 EGC tissues, we performed immunohistochemical staining for CD44v9 and Ki-67. The whole patients were divided into three groups (group A, CD44v9- negative/Ki-67–low; group B, neither group A or C; and group C, CD44v9-positive/Ki-67– high). Its clinical significance was re-analyzed with adjustment via propensity score matching (PSM). For validation, we performed bootstrap resampling.
Results
The median follow-up duration was 90.4 months (range, 3.7 to 120.4 months). In the comparison according to CD44v9/Ki-67 expression, the combined use of the two biomarker clearly separated the three groups by 5-year survival rates (5-YSR, 96.3%, 89.8%, and 76.8% in group A, B, and C, respectively; p=0.009). After PSM, 5-YSR were 97.7% and 76.8% in group A+B and group C, respectively (p=0.002). Multivariable analysis demonstrated that group C had independently poor prognosis (hazard ratio, 9.137; 95% confidence interval, 1.187 to 70.366; p=0.034) compared with group A. Bootstrap resampling internally validated this result (p=0.016).
Conclusion
This study suggests that both positive CD44v9 and high Ki-67 expression are associated with poor prognosis in EGC, and the combined use of these markers provides better prognostic stratification than the single use of them.

Citations

Citations to this article as recorded by

The Prognostic Importance of Ki-67 in Gastrointestinal Carcinomas: A Meta-analysis and Multi-omics Approach
Mahdieh Razmi, Fatemeh Tajik, Farideh Hashemi, Ayna Yazdanpanah, Fatemeh Hashemi-Niasari, Adeleh Divsalar
Journal of Gastrointestinal Cancer.2024; 55(2): 599. CrossRef
Impact of Alcian blue and periodic acid Schiff expression on the prognosis of gastric signet ring cell carcinoma
Juan Lin, Zhu-Feng Chen, Guo-Dong Guo, Xin Chen
World Journal of Gastrointestinal Oncology.2024; 16(3): 687. CrossRef
Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues
Su-nan Wang, Yang-kun Wang, Chao-ya Zhu, Bo Jiang, Dong-feng Ge, Ying-ying Li
Clinical and Translational Oncology.2024;[Epub] CrossRef
Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: A SEER data-based study
Jinzhou Li, Ting Cui, Zeping Huang, Yanxi Mu, Yalong Yao, Wei Xu, Kang Chen, Haipeng Liu, Wenjie Wang, Xiao Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis (Review)
Hiroshi Kobayashi, Shogo Imanaka, Hiroshi Shigetomi
Oncology Letters.2022;[Epub] CrossRef
Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer
Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Current Issues in Molecular Biology.2022; 44(3): 1395. CrossRef
Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study
Lanqing Cao, Zhaoyong Wang, Liwei Duan, Lijuan Wei
Journal of Gastrointestinal Surgery.2021; 25(7): 1706. CrossRef
Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma
Jinbo Song, Zhe Yu, Bingqi Dong, Mingkai Zhu, Xiaofeng Guo, Yongkang Ma, Shiming Zhao, Tiejun Yang
World Journal of Surgical Oncology.2021;[Epub] CrossRef
Fascin‑1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma
Yumiko Yamamoto, Yoshihiro Hayashi, Hideyuki Sakaki, Ichiro Murakami
Molecular and Clinical Oncology.2021;[Epub] CrossRef
Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
Jie Yang
Medical Oncology.2020;[Epub] CrossRef
Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression
Jinfen Wei, Meiling Hu, Kaitang Huang, Shudai Lin, Hongli Du
International Journal of Molecular Sciences.2020; 21(17): 5983. CrossRef

7,854 View
178 Download
14 Web of Science
11 Crossref

CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer: Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Rock Bum Kim, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha; Cancer Res Treat. 2016;48(1):142-152. Published online March 17, 2015; DOI: https://doi.org/10.4143/crt.2014.227

Abstract PDF PubReader ePub

Purpose
The present study is to investigate the significance of CD44 variant 9 (CD44v9) expression as a biomarker in primary gastric cancer.
Materials and Methods
With various gastric tissues, we performed immunohistochemical staining for CD44v9.
Results
The positive expression rates for CD44v9 in tumor, including adenoma, early gastric cancer (EGC), and advanced gastric cancer (AGC), were higher than those in non-tumor tissues (p = 0.003). In addition, the higher expression for CD44v9 was observed as the tissue becomes malignant. In the analysis of 333 gastric cancer tissues, we found that positive expression rates for CD44v9 were higher in the intestinal type or well differentiated gastric cancer than in the diffuse type or poorly differentiated gastric cancer. Interestingly, the positive expression indicated poor prognosis in EGC (5-YSR in stage I, 81.7% vs 95.2%; p = 0.013), but not in AGC (5-YSR in stage II, 66.9% vs 62.2%; p = 0.821, 5-YSR in stage III, 34.5% vs 32.0%; p = 0.929). Moreover, strong positive expression (3+) showed a trend suggesting worse prognosis only in EGC, and it appeared to be associated with lymph node metastasis.
Conclusion
This study suggests that CD44v9 may be a good biomarker for prognosis prediction and for chemoprevention or biomarker-driven therapies only for EGC.

Citations

Citations to this article as recorded by

Single-cell RNA-seq reveals MIF−(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma
Wei Chen, Xinnian Yu, Huixin Li, Shenglong Yuan, Yuqi Fu, Huanhuan Hu, Fangzhou Liu, Yuan Zhang, Shanliang Zhong
Oral Oncology.2024; 148: 106654. CrossRef
Can Nano Yield Big Insights? Oligonucleotide-Based Biosensors in Early Diagnosis of Gastric Cancer
Alexandra E. Avanu, Alexandra M. Ciubotariu, Gianina Dodi
Chemosensors.2024; 12(3): 44. CrossRef
Diagnostic and prognostic value of CD44v9 and TIM3 expression in CK‑ and CK+ regions in gastric cancer tissues
Xiaofei Wang, Lin Lu, Ruidong Yang, Zhiwu Wang, Qingke Li, Jingwu Li, Yankun Liu
Oncology Letters.2024;[Epub] CrossRef
Late recurrent gastric carcinoma 12 years after surgery with attenuation of CD44 variant 9 expression
Hirokatsu Hayashi, Itaru Yasufuku, Toshiya Higashi, Wakana Chikaishi, Ryoma Yokoi, Masahiro Fukada, Yuta Sato, Ryuichi Asai, Jesse Yu Tajima, Chiemi Saigo, Akitaka Makiyama, Yoshihiro Tanaka, Naoki Okumura, Katsutoshi Murase, Takao Takahashi, Manabu Futam
Surgical Case Reports.2023;[Epub] CrossRef
The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer
Nicola Cirillo
International Journal of Molecular Sciences.2023; 24(21): 15812. CrossRef
Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer
Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Current Issues in Molecular Biology.2022; 44(3): 1395. CrossRef
Molecular pathogenesis and emerging targets of gastric adenocarcinoma
Abby Ivey, Hillary Pratt, Brian A. Boone
Journal of Surgical Oncology.2022; 125(7): 1079. CrossRef
Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
Cancer Cell International.2021;[Epub] CrossRef
CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations
Mohammad Mahmoudi Gomari, Marziye Farsimadan, Neda Rostami, Zahra mahmoudi, Mahmood Fadaie, Ibrahim Farhani, Parastoo Tarighi
Mutation Research/Reviews in Mutation Research.2021; : 108374. CrossRef
Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation
Tomoko Jogo, Eiji Oki, Ryota Nakanishi, Koji Ando, Yuichiro Nakashima, Yasue Kimura, Hiroshi Saeki, Yoshinao Oda, Yoshihiko Maehara, Masaki Mori
Gastric Cancer.2021; 24(5): 1089. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer
Luis Enrique Cortés-Hernández, Zahra Eslami-S, Catherine Alix-Panabières
Molecular Aspects of Medicine.2020; 72: 100816. CrossRef
Decrease in MiR-148a Expression During Initiation of Chief Cell Transdifferentiation
Takahiro Shimizu, Yoojin Sohn, Eunyoung Choi, Christine P. Petersen, Nripesh Prasad, James R. Goldenring
Cellular and Molecular Gastroenterology and Hepatology.2020; 9(1): 61. CrossRef
Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
Jie Yang
Medical Oncology.2020;[Epub] CrossRef
Trop2 is upregulated in the transition to dysplasia in the metaplastic gastric mucosa
Katherine M Riera, Bogun Jang, Jimin Min, Joseph T Roland, Qing Yang, William T Fesmire, Sophie Camilleri‐Broet, Lorenzo Ferri, Woo H Kim, Eunyoung Choi, James R Goldenring
The Journal of Pathology.2020; 251(3): 336. CrossRef
Prognostic value of CD44v9 expression in human cancers: Retraction
Li Zeng, Yitian Chen, Ligang Chen, Chengwei Tang
Medicine.2020; 99(30): e20428. CrossRef
Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression
Jinfen Wei, Meiling Hu, Kaitang Huang, Shudai Lin, Hongli Du
International Journal of Molecular Sciences.2020; 21(17): 5983. CrossRef
The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation
Takaki Akamine, Tetsuzo Tagawa, Kayo Ijichi, Gouji Toyokawa, Shinkichi Takamori, Fumihiko Hirai, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara
Annals of Surgical Oncology.2019; 26(5): 1544. CrossRef
Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
Hitoshi Tsugawa, Chihiro Kato, Hideki Mori, Juntaro Matsuzaki, Kaori Kameyama, Hideyuki Saya, Masanori Hatakeyama, Makoto Suematsu, Hidekazu Suzuki
Cellular and Molecular Gastroenterology and Hepatology.2019; 8(3): 319. CrossRef
hnRNPK promotes gastric tumorigenesis through regulating CD44E alternative splicing
Wei-zhao Peng, Ji-xi Liu, Chao-feng Li, Ren Ma, Jian-zheng Jie
Cancer Cell International.2019;[Epub] CrossRef
The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Cancer Research and Treatment.2019; 51(4): 1411. CrossRef
Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer
Masayuki Hagiwara, Eiji Kikuchi, Nobuyuki Tanaka, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
BMC Cancer.2018;[Epub] CrossRef
Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma
Noriko Hiyama, Takahiro Ando, Keita Maemura, Toshio Sakatani, Yosuke Amano, Kousuke Watanabe, Hidenori Kage, Yutaka Yatomi, Takahide Nagase, Jun Nakajima, Daiya Takai
Japanese Journal of Clinical Oncology.2018; 48(4): 303. CrossRef
Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation
Nattawan Suwannakul, Ning Ma, Raynoo Thanan, Somchai Pinlaor, Piti Ungarreevittaya, Kaoru Midorikawa, Yusuke Hiraku, Shinji Oikawa, Shosuke Kawanishi, Mariko Murata
Mediators of Inflammation.2018; 2018: 1. CrossRef
Expression of CD44, CD44v9, ABCG2, CD24, Bmi‑1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors
Tetsuya Tamatani, Natsumi Takamaru, Go Ohe, Kazuya Akita, Takayuki Nakagawa, Youji Miyamoto
Oncology Letters.2018;[Epub] CrossRef
Hyaluronic acid in digestive cancers
Ruo-Lin Wu, Lei Huang, Hong-Chuan Zhao, Xiao-Ping Geng
Journal of Cancer Research and Clinical Oncology.2017; 143(1): 1. CrossRef
Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
Gyung Hyuck Ko, Se-Il Go, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Medicine.2017; 96(25): e7181. CrossRef
Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)
Kohei Shitara, Toshihiko Doi, Osamu Nagano, Chiyo K. Imamura, Takeshi Ozeki, Yuya Ishii, Kenji Tsuchihashi, Shunji Takahashi, Takako E. Nakajima, Shuichi Hironaka, Miki Fukutani, Hiromi Hasegawa, Shogo Nomura, Akihiro Sato, Yasuaki Einaga, Takeshi Kuwata,
Gastric Cancer.2017; 20(2): 341. CrossRef
CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues
Yushi YAMAKAWA, Masatoshi KUSUHARA, Masanori TERASHIMA, Yusuke KINUGASA, Takashi SUGINO, Masato ABE, Toru MOCHIZUKI, Keiichi HATAKEYAMA, Kenjiro KAMI, Ken YAMAGUCHI
Biomedical Research.2017; 38(1): 41. CrossRef
Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells
Yana Zavros
Cellular and Molecular Gastroenterology and Hepatology.2017; 4(1): 55. CrossRef
Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)
Kohei Shitara, Toshihiko Doi, Osamu Nagano, Miki Fukutani, Hiromi Hasegawa, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Kai Asai, Yasuaki Einaga, Kenji Tsuchihashi, Kentaro Suina, Yusuke Maeda, Hideyuki Saya, Atsushi Ohtsu
Gastric Cancer.2017; 20(6): 1004. CrossRef
Hypoxia regulates CD44 expression via hypoxia-inducible factor-1α in human gastric cancer cells
Gai Liang, Shuang Li, Wei Du, Qinghua Ke, Jun Cai, Jiyuan Yang
Oncology Letters.2017; 13(2): 967. CrossRef
Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality
Masayuki Hagiwara, Eiji Kikuchi, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
Urologic Oncology: Seminars and Original Investigations.2016; 34(8): 337.e19. CrossRef
Cancer stem cells in human digestive tract malignancies
Fatemeh B. Rassouli, Maryam M. Matin, Morvarid Saeinasab
Tumor Biology.2016; 37(1): 7. CrossRef

13,851 View
123 Download
38 Web of Science
34 Crossref

Up-regulation of RhoGDI2 in Human Breast Cancer and Its Prognostic Implications: Hyeong-Gon Moon, Sang-Ho Jeong, Young-Tae Ju, Chi-Young Jeong, Jong Sil Lee, Young-Joon Lee, Soon-Chan Hong, Sang-Kyung Choi, Woo-Song Ha, Soon-Tae Park, Eun-Jung Jung; Cancer Res Treat. 2010;42(3):151-156. Published online September 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.3.151

Abstract PDF PubReader ePub

Purpose

Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial.

Materials and Methods

We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches.

Results

By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter disease-free survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15).

Conclusion

Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.

Citations

Citations to this article as recorded by

Differential functions of RhoGDIβ in malignant transformation and progression of urothelial cell following N-butyl-N-(4-hydmoxybutyl) nitrosamine exposure
Xiaohui Hua, Ronghao Zou, Xiaoyue Bai, Yuyao Yang, Juan Lu, Chuanshu Huang
BMC Biology.2023;[Epub] CrossRef
Systematic investigation of biomarker-like role of ARHGDIB in breast cancer
Xiaonan Wang, Xiaomin Bi, Xing Huang, Bijun Wang, Qianying Guo, Zhengsheng Wu
Cancer Biomarkers.2020; 28(1): 101. CrossRef
Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer
Stefan Steurer, Benjamin Hager, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Sarah Minner, Till S. Clauditz, Claudia Hube-Magg, Andreas M. Luebke, Ronald Simon, Jakob R. Izbicki, Eike Burandt, Guido Sauter, Christoph Fraune, Sören Weid
Aging.2019; 11(18): 7859. CrossRef
Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation
Ming-Chun Lai, Qian-Qian Zhu, Kwabena-Gyabaah Owusu-Ansah, Yang-Bo Zhu, Zhe Yang, Hai-Yang Xie, Lin Zhou, Li-Ming Wu, Shu-Sen Zheng
Oncology Letters.2017; 14(2): 1395. CrossRef
RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway
Huiyan Niu, Baogang Wu, Yang Peng, Hongfang Jiang, Yi Zhang, Jiahe Wang, Yifei Zhang, Ping He
Tumor Biology.2015; 36(1): 409. CrossRef
Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors
Jonathan Hensel, Jason E. Duex, Charles Owens, Garrett M. Dancik, Michael G. Edwards, Henry F. Frierson, Dan Theodorescu
Molecular Cancer Research.2015; 13(9): 1306. CrossRef
Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9
Marcos A. Muñiz Lino, Yadira Palacios-Rodríguez, Sergio Rodríguez-Cuevas, Verónica Bautista-Piña, Laurence A. Marchat, Erika Ruíz-García, Horacio Astudillo-de la Vega, Ana E. González-Santiago, Ali Flores-Pérez, José Díaz-Chávez, Ángeles Carlos-Reyes, Eli
Journal of Proteomics.2014; 111: 198. CrossRef
Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway
Weiming Duan, Yaxiang Xu, YuJin Dong, Lili Cao, Jian Tong, Xinwen Zhou
Journal of Radiation Research.2013; 54(4): 611. CrossRef
Expression of a tumor-associated gene, LASS2, in the human bladder carcinoma cell lines BIU-87, T24, EJ and EJ-M3
QINGHUA ZHAO, HAIFENG WANG, MINGYING YANG, DELIN YANG, YIGANG ZUO, JIANSONG WANG
Experimental and Therapeutic Medicine.2013; 5(3): 942. CrossRef
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration
Neveen Said, Marta Sanchez-Carbayo, Steven C. Smith, Dan Theodorescu
Journal of Clinical Investigation.2012; 122(4): 1503. CrossRef
Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma
Xianzheng Li, Jianmei Wang, Xiaojing Zhang, Yuanfeng Zeng, Li Liang, Yanqing Ding
Annals of Surgical Oncology.2012; 19(1): 145. CrossRef
Expression and prognostic significance of a new tumor metastasis suppressor gene LASS2 in human bladder carcinoma
Haifeng Wang, Jiansong Wang, Yigang Zuo, Mingxia Ding, Ruping Yan, Delin Yang, Changxin Ke
Medical Oncology.2012; 29(3): 1921. CrossRef
The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder
T Qayyum, G Fyffe, M Duncan, P A McArdle, M Hilmy, C Orange, G Halbert, M Seywright, P G Horgan, M A Underwood, J Edwards
British Journal of Cancer.2012; 106(6): 1187. CrossRef
The faces and friends of RhoGDI2
Erin M. Griner, Dan Theodorescu
Cancer and Metastasis Reviews.2012; 31(3-4): 519. CrossRef
Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade
MIGUEL A. FONSECA-SÁNCHEZ, SERGIO RODRÍGUEZ CUEVAS, GUILLERMO MENDOZA-HERNÁNDEZ, VERONICA BAUTISTA-PIÑA, ELENA ARECHAGA OCAMPO, ALFREDO HIDALGO MIRANDA, VALERIA QUINTANAR JURADO, LAURENCE A. MARCHAT, ELIZBETH ÁLVAREZ-SÁNCHEZ, CARLOS PÉREZ PLASENCIA, CÉSAR
International Journal of Oncology.2012; 41(2): 670. CrossRef
Reactive Center Loop Moiety Is Essential for the Maspin Activity on Cellular Invasion and Ubiquitin‐Proteasome Level
Chakkrit Khanaree, Kongthawat Chairatvit, Sittiruk Roytrakul, Ariyaphong Wongnoppavich
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2012; 20(9): 427. CrossRef
NFIB is a potential target for estrogen receptor‐negative breast cancers
Hyeong-Gon Moon, Ki-Tae Hwang, Jeong-Ah Kim, Hee Sung Kim, Min-Joo Lee, Eun-Mi Jung, Eunyoung Ko, Wonshik Han, Dong-Young Noh
Molecular Oncology.2011; 5(6): 538. CrossRef

11,410 View
73 Download
17 Crossref

First
Prev
Page of 1
Next
Last

Search